(CercleFinance.com) – Novo Nordisk announced on Friday that it would only be able to supply limited quantities of Wegovy, its obesity treatment which is enjoying growing success in the United States.
In an information note, the Danish laboratory explains that the activity trends which today surround the demand for the product in the American market exceed its annual production capacities.
Faced with the strong interest surrounding this prescription-only weight loss drug, the biopharmaceutical group has indicated that it will only be able to offer pharmacies limited quantities of its single-use pre-filled pens for injecting doses of 0.25mg, 0.5mg and 1mg.
The 1.7 mg and 2.4 mg solutions for subcutaneous injection are not yet affected by these supply difficulties.
In order to avoid too much excitement around the product, Novo indicates that it has decided to interrupt its promotional efforts around Wegovy.
Wegovy is currently approved in Canada, the United States and the United Kingdom and has received a positive opinion in its review procedure in the European Union.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
